{
  "abstract": "Histiocytic sarcoma is a rare and aggressive malignancy with poor outcomes under conventional chemotherapy. Activating MAPK pathway alterations, including BRAF V600E mutations, provide a rationale for targeted therapy; however, the durability of responses and the role of post-transplant maintenance remain unclear. We report a patient with refractory BRAF V600E-mutant histiocytic sarcoma who achieved complete remission following BRAF/MEK inhibition and subsequently underwent allogeneic stem cell transplantation. Post-transplant maintenance therapy with dabrafenib and trametinib was initiated early after engraftment. The patient achieved sustained complete remission with no radiological or molecular evidence of disease during follow-up exceeding one year. Circulating tumor DNA analysis remained negative for previously detected mutations. This case suggests that an integrated strategy combining targeted therapy, allogeneic transplantation, and post-transplant maintenance may enable durable disease control in high-risk BRAF-mutant histiocytic sarcoma and warrants further evaluation.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology and Oncology, Carreras Leukämie Centrum, Philipps-Universität Marburg, University Hospital Giessen and Marburg, Marburg, Germany. ihab.karim@uni-marburg.de.",
    "Department of Hematology and Oncology, University Hospital Giessen and Marburg, Giessen, Germany.",
    "Institute of Pathology, University Hospital Giessen and Marburg, Giessen, Germany.",
    "Department of Hematology and Oncology, Carreras Leukämie Centrum, Philipps-Universität Marburg, University Hospital Giessen and Marburg, Marburg, Germany."
  ],
  "article_type": "case report",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ihab Karim",
      "orcid": "0009-0003-0456-9544"
    },
    {
      "affs": [
        1
      ],
      "name": "Tobias Arnold"
    },
    {
      "affs": [
        2
      ],
      "name": "Andreas Bräuninger"
    },
    {
      "affs": [
        3
      ],
      "name": "Marius Dohse"
    },
    {
      "affs": [
        1
      ],
      "name": "Felix Schell"
    },
    {
      "affs": [
        1
      ],
      "name": "Maisun Abu Samra"
    },
    {
      "affs": [
        3
      ],
      "name": "Thomas Tarawneh"
    },
    {
      "affs": [
        3
      ],
      "name": "Andreas Burchert"
    },
    {
      "affs": [
        2
      ],
      "name": "Stefan Gattenlöhner"
    },
    {
      "affs": [
        3
      ],
      "name": "Kristina Sohlbach"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ehb5g2nkrr24g.bib",
  "cited_by": 0,
  "doi": "10.1007/s00277-026-07277-6",
  "fulltext_url": "https://europepmc.org/articles/PMC13719762",
  "id": "ehb5g2nkrr24g",
  "issns": [
    "0939-5555",
    "1432-0584"
  ],
  "landing_url": "https://europepmc.org/article/MED/42957845",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Case Report"
    ],
    [
      "openalex",
      "2737|Histiocytic Disorders and Treatments"
    ]
  ],
  "openalex": "W7224096466",
  "pdf_url": "https://europepmc.org/articles/PMC13719762?pdf=render",
  "pmcid": "PMC13719762",
  "pmid": "42957845",
  "published": "2026-10-28",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/ehb5g2nkrr24g.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T00:20:36Z",
      "native_id": "MED:42957845",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42957845"
    },
    {
      "first_seen": "2026-11-02T12:23:40Z",
      "native_id": "PMC13719762",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s00277-026-07277-6"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Histiocytic Disorders and Treatments",
      "subfield": "physiology"
    }
  ],
  "title": "Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.",
  "title_text": "Post-transplant BRAF/MEK inhibitor maintenance sustains complete remission in BRAF V600E-mutant histiocytic sarcoma.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:20:46Z",
  "url": "https://research.draconitic.com/paper/ehb5g2nkrr24g",
  "venue": "Annals of hematology",
  "versions": []
}